Hinge Health (NYSE:HNGE) Reaches New 12-Month High Following Earnings Beat

Posted by Francis Steltz on Nov 4th, 2026

Hinge Health Inc. (NYSE:HNGE – Get Free Report) reached a new 52-week high during trading on Monday following a stronger than expected earnings report. The company traded as high as $118.74 and last traded at $117.8360, with a volume of 410,996 shares trading hands. The stock had previously closed at $114.32.

The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.44. Hinge Health had a net margin of 21.02% and a return on equity of 73.91%. The firm had revenue of $234.97 million during the quarter. During the same period in the prior year, the business posted ($0.02) EPS. The company’s revenue for the quarter was up 52.4% on a year-over-year basis.

Trending Headlines about Hinge Health

Here are the key news stories impacting Hinge Health this week:

Positive Sentiment: Third-quarter revenue rose 52% year over year to about $235 million, ahead of forecasts, and earnings also beat expectations. Fierce Healthcare article
Positive Sentiment: Management forecast fourth-quarter revenue of $249 million–$251 million and 2026 revenue of $879 million–$881 million, both above analyst consensus—reinforcing expectations for continued growth. Seeking Alpha article
Positive Sentiment: Several analysts raised price targets after the results. Truist set the highest cited target at $145; Morgan Stanley, RBC, Canaccord and Stifel also lifted targets and maintained bullish ratings. MSN article
Neutral Sentiment: Hinge Health is expanding beyond musculoskeletal care into areas such as migraine and gastrointestinal programs, while exploring hardware acquisitions. These initiatives offer potential growth but will take time to develop. Fierce Healthcare article
Negative Sentiment: After a reported 156% year-to-date rally, the stock is near its 52-week high, leaving less room for disappointment. One analysis also noted that results, despite topping published estimates, fell short of higher market expectations. Yahoo Finance UK article

Analyst Ratings Changes

HNGE has been the topic of several recent analyst reports. Royal Bank Of Canada upped their price target on Hinge Health from $110.00 to $135.00 and gave the company an “outperform” rating in a research report on Tuesday. Weiss Ratings lowered Hinge Health from a “hold (c)” rating to a “hold (c-)” rating in a research report on Thursday, October 8th. Barclays lifted their target price on Hinge Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Needham & Company LLC upped their target price on Hinge Health from $115.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Zacks Research lowered shares of Hinge Health from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, Hinge Health has a consensus rating of “Moderate Buy” and a consensus target price of $118.93.

Get Our Latest Report on Hinge Health

Insider Transactions at Hinge Health

In other Hinge Health news, CFO James Budge sold 55,561 shares of the company’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $89.45, for a total value of $4,969,931.45. Following the transaction, the chief financial officer directly owned 349,062 shares of the company’s stock, valued at $31,223,595.90. This represents a 13.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President James Pursley sold 33,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $88.05, for a total value of $2,905,650.00. Following the sale, the president directly owned 706,235 shares of the company’s stock, valued at $62,183,991.75. This trade represents a 4.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 1,024,581 shares of company stock worth $95,632,761. 18.92% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hinge Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HNGE. 11.2 Capital Management LLC acquired a new stake in shares of Hinge Health in the 2nd quarter valued at $204,566,531. Assenagon Asset Management S.A. boosted its holdings in Hinge Health by 2,141.9% in the third quarter. Assenagon Asset Management S.A. now owns 1,854,922 shares of the company’s stock worth $180,373,000 after purchasing an additional 1,772,182 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in Hinge Health by 225.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,163,187 shares of the company’s stock worth $44,852,000 after buying an additional 806,007 shares during the last quarter. Wellington Management Group LLP increased its position in Hinge Health by 169.7% during the second quarter. Wellington Management Group LLP now owns 1,205,584 shares of the company’s stock worth $100,063,000 after buying an additional 758,594 shares during the last quarter. Finally, Estuary Capital Management LP acquired a new position in Hinge Health during the first quarter worth $15,201,000.

Hinge Health Price Performance

The company has a fifty day simple moving average of $99.21 and a two-hundred day simple moving average of $67.72. The company has a market capitalization of $9.75 billion, a P/E ratio of 61.62 and a beta of 1.19.

About Hinge Health

(Get Free Report)

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.